FDA says no to AZ’s Fasenra for nasal polyp indication
Summary : AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic…
Summary : AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic…
Summary : Results from a phase 3 trial evaluating AstraZeneca and Sanofi’s jointly developed treatment nirsevimab – the first investigational long-acting antibody, designed to protect…
Summary : AstraZeneca and Sanofi secured accelerated authorization for respiratory syncytial virus (RSV) antibody nirsevimab from the European Medicines Agency. Nirsevimab was…
Synopsis: Neurimmune AG, a biopharmaceutical company, announced that it has entered into an exclusive global collaboration and license agreement with Alexion, AstraZeneca’s…